12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

INX-189: Phase II ongoing

Inhibitex said it plans to submit a protocol amendment to FDA this quarter to expand a double-blind, placebo-controlled, U.S. Phase II trial with INX-189 in patients with chronic HCV genotype 2 and 3 infection to include additional cohorts evaluating once-daily 100 and 200 mg INX-189 in combination with ribavirin for 12 weeks. The decision...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >